Cytek Biosciences, Inc.
CTKB
$3.96
$0.195.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.46% | 8.12% | 1.54% | -2.18% | -7.59% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.46% | 8.12% | 1.54% | -2.18% | -7.59% |
| Cost of Revenue | 7.42% | 22.80% | 9.99% | 2.62% | -2.50% |
| Gross Profit | 5.44% | -2.28% | -5.01% | -6.17% | -12.41% |
| SG&A Expenses | 18.52% | 40.94% | 18.90% | 7.11% | 6.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.93% | 24.31% | 10.29% | 1.96% | 1.51% |
| Operating Income | -23.29% | -287.34% | -116.38% | -24.59% | -39.51% |
| Income Before Tax | -54.21% | -139.05% | -5,048.41% | 5.72% | -25.28% |
| Income Tax Expenses | 997.79% | 5,788.97% | -192.22% | -136.70% | 104.82% |
| Earnings from Continuing Operations | -65.46% | -557.08% | -682.15% | 46.49% | -84.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -65.46% | -557.08% | -682.15% | 46.49% | -84.83% |
| EBIT | -23.29% | -287.34% | -116.38% | -24.59% | -39.51% |
| EBITDA | -26.70% | -176.40% | -203.46% | -29.99% | -44.99% |
| EPS Basic | -65.09% | -560.37% | -695.83% | 44.58% | -88.54% |
| Normalized Basic EPS | -53.73% | -139.40% | -5,542.86% | 2.34% | -27.97% |
| EPS Diluted | -66.67% | -582.33% | -695.83% | 45.00% | -80.00% |
| Normalized Diluted EPS | -53.73% | -139.40% | -5,542.86% | 2.34% | -27.97% |
| Average Basic Shares Outstanding | 0.28% | -0.71% | -2.64% | -3.43% | -1.97% |
| Average Diluted Shares Outstanding | 0.28% | -0.71% | -3.94% | -3.43% | -1.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |